Condition
Advanced Malignant Solid Neoplasm|Advanced Peritoneal Malignant Mesothelioma|Advanced Pleural Malignant Mesothelioma|Recurrent Malignant Solid Neoplasm|Recurrent Peritoneal Malignant Mesothelioma|Recurrent Pleural Malignant Mesothelioma|Stage III Non-Small Cell Lung Cancer|Stage III Ovarian Cancer|Stage III Pleural Mesothelioma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIA Ovarian Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IIIB Ovarian Cancer|Stage IIIC Ovarian Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IV Ovarian Cancer|Stage IV Pleural Mesothelioma|Thymoma|Unresectable Solid Neoplasm
Estimated Enrollment: 58
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment
Study ID Numbers: NCI-2015-00127|PHI-76|9837|P30CA033572|UM1CA186689|UM1CA186705|UM1CA186717|ZIABC011078
Study First Received: August 27, 2015
Last Updated: March 23, 2017
Estimated Primary Completion Date: August 2017
Primary Outcome Measures:
Dose-limiting toxicity, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Arm A)|Response rate using RECIST (Arm B)|Establishment of pleural and peritoneal effluent-derived cell lines|Objective clinical response|Pharmacokinetic (PK) parameter|Response of cultured pleural and peritoneal mesothelioma cells to cisplatin, pemetrexed, and methoxyamine
Sponsors and Collaborators:
National Cancer Institute (NCI)
Website Link: https://ClinicalTrials.gov/show/NCT02535312
